HEALTHCARE
Global Antibacterial Drugs Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Antibacterial Drugs Market, By Distribution Channel (Hospital Pharmacies, Drug Stores and Rental Pharmacies, and Online Antibacterial Drug Sales), Route of Administration (Enteral, Parental, and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
Market Dynamics
- Increasing prevalence of drug-resistant bacterial infections
- Advancements in antibacterial drug development technologies
- Rising concerns regarding antibiotic resistance
- Regulatory hurdles
- Rise of personalised medicine in antibacterial treatments
- AI integration in antibacterial drug discovery
- Limited financial incentives and return on investment
- Innovation and research gaps
SEGMENTATION
- Distribution Channel
- Hospital Pharmacies
- Drug Stores and Rental Pharmacies
- Online Antibacterial Drug Sales
- Route of Administration
- Enteral
- Parental
- Others
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- AbbVie, Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Viatris, Inc.
- Melinta Therapeutics LLC
- Cipla, Inc.
- Shionogi & Co., Ltd.
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Antibacterial Drugs Market, by Distribution Channel
- 3.2 Global Antibacterial Drugs Market, by Route of Administration
- 3.3 Global Antibacterial Drugs Market, by Geography
- 3.4 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Growing embrace of combination therapies
- 5.1.2 Digital health and telemedicine
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Increasing prevalence of drug-resistant bacterial infections
- 5.2.2 Advancements in antibacterial drug development technologies
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 Rising concerns regarding antibiotic resistance
- 5.3.2 Regulatory hurdles
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Rise of personalised medicine in antibacterial treatments
- 5.4.2 AI integration in antibacterial drug discovery
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Limited financial incentives and return on investment
- 5.5.2 Innovation and research gaps
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL ANTIBACTERIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Distribution Channel Summary
- 6.2 Market Attractive Index
- 6.3 Global Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- SECTION 7 - GLOBAL ANTIBACTERIAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 7.1 Route of Administration Summary
- 7.2 Market Attractive Index
- 7.3 Global Antibacterial Drugs Market, by Route of Administration (2019-2032)
- SECTION 8 - GLOBAL ANTIBACTERIAL DRUGS MARKET, BY GEOGRAPHY
- 8.1 Regional Summary
- 8.2 Market Attractive Index
- 8.3 Global Antibacterial Drugs Market, by Geography (2019-2032)
- SECTION 9 - NORTH AMERICA ANTIBACTERIAL DRUGS MARKET
- 9.1 North America Summary
- 9.2 Market Attractive Index
- 9.3 North America Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- 9.4 North America Antibacterial Drugs Market, by Route of Administration (2019-2032)
- 9.5 North America Antibacterial Drugs Market, by Country (2019-2032)
- 9.5.1 U.S.
- 9.5.2 Canada
- 9.5.3 Mexico
- 9.5.4 Rest of North America
- SECTION 10 - EUROPE ANTIBACTERIAL DRUGS MARKET
- 10.1 Europe Summary
- 10.2 Market Attractive Index
- 10.3 Europe Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- 10.4 Europe Antibacterial Drugs Market, by Route of Administration (2019-2032)
- 10.5 Europe Antibacterial Drugs Market, by Country (2019-2032)
- 10.5.1 Germany
- 10.5.2 U.K.
- 10.5.3 France
- 10.5.4 Italy
- 10.5.5 Spain
- 10.5.6 Russia
- 10.5.7 The Netherlands
- 10.5.8 Belgium
- 10.5.9 Turkey
- 10.5.10 Rest of Europe
- SECTION 11 - ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET
- 11.1 Asia-Pacific Summary
- 11.2 Market Attractive Index
- 11.3 Asia-Pacific Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- 11.4 Asia-Pacific Antibacterial Drugs Market, by Route of Administration (2019-2032)
- 11.5 Asia-Pacific Antibacterial Drugs Market, by Country (2019-2032)
- 11.5.1 China
- 11.5.2 India
- 11.5.3 Japan
- 11.5.4 South Korea
- 11.5.5 Singapore
- 11.5.6 Malaysia
- 11.5.7 Australia
- 11.5.8 Thailand
- 11.5.9 Philippines
- 11.5.10 Rest of Asia-Pacific
- SECTION 12 - SOUTH AMERICA ANTIBACTERIAL DRUGS MARKET
- 12.1 South America Summary
- 12.2 Market Attractive Index
- 12.3 South America Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- 12.4 South America Antibacterial Drugs Market, by Route of Administration (2019-2032)
- 12.5 South America Antibacterial Drugs Market, by Country (2019-2032)
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Chile
- 12.5.4 Colombia
- 12.5.5 Rest of South America
- SECTION 13 - MIDDLE EAST AND AFRICA ANTIBACTERIAL DRUGS MARKET
- 13.1 Middle East and Africa Summary
- 13.2 Market Attractive Index
- 13.3 Middle East and Africa Antibacterial Drugs Market, by Distribution Channel (2019-2032)
- 13.4 Middle East and Africa Antibacterial Drugs Market, by Route of Administration (2019-2032)
- 13.5 Middle East and Africa Antibacterial Drugs Market, by Country (2019-2032)
- 13.5.1 Kingdom of Saudi Arabia
- 13.5.2 South Africa
- 13.5.3 U.A.E.
- 13.5.4 Egypt
- 13.5.5 Rest of Middle East and Africa
- SECTION 14 - COMPANY SHARE ANALYSIS
- 14.1 Global Antibacterial Drugs Market, Company Share Analysis
- 14.2 North America Antibacterial Drugs Market, Company Share Analysis
- 14.3 Europe Antibacterial Drugs Market, Company Share Analysis
- 14.4 Asia-Pacific Antibacterial Drugs Market, Company Share Analysis
- SECTION 15 - COMPANY PROFILES
- 15.1 AbbVie, Inc.
- 15.1.1 Company Snapshot
- 15.1.2 Financial Overview
- 15.1.3 Product Portfolio
- 15.1.4 Recent Developments
- 15.2 Pfizer Inc.
- 15.2.1 Company Snapshot
- 15.2.2 Financial Overview
- 15.2.3 Product Portfolio
- 15.2.4 Recent Developments
- 15.3 Novartis AG
- 15.3.1 Company Snapshot
- 15.3.2 Financial Overview
- 15.3.3 Product Portfolio
- 15.3.4 Recent Developments
- 15.4 Merck & Co., Inc.
- 15.4.1 Company Snapshot
- 15.4.2 Financial Overview
- 15.4.3 Product Portfolio
- 15.4.4 Recent Developments
- 15.5 Teva Pharmaceutical Industries Ltd.
- 15.5.1 Company Snapshot
- 15.5.2 Financial Overview
- 15.5.3 Product Portfolio
- 15.5.4 Recent Developments
- 15.6 Lupin Pharmaceuticals, Inc.
- 15.6.1 Company Snapshot
- 15.6.2 Financial Overview
- 15.6.3 Product Portfolio
- 15.6.4 Recent Developments
- 15.7 Viatris, Inc.
- 15.7.1 Company Snapshot
- 15.7.2 Financial Overview
- 15.7.3 Product Portfolio
- 15.7.4 Recent Developments
- 15.8 Melinta Therapeutics LLC
- 15.8.1 Company Snapshot
- 15.8.2 Financial Overview
- 15.8.3 Product Portfolio
- 15.8.4 Recent Developments
- 15.9 Cipla, Inc.
- 15.9.1 Company Snapshot
- 15.9.2 Financial Overview
- 15.9.3 Product Portfolio
- 15.9.4 Recent Developments
- 15.10 Shionogi & Co., Ltd.
- 15.10.1 Company Snapshot
- 15.10.2 Financial Overview
- 15.10.3 Product Portfolio
- 15.10.4 Recent Developments
- SECTION 16 - RELATED REPORTS
- SECTION 17 - DISCLAIMER
RESEARCH METHODOLOGY
RESEARCH AND DATA COLLECTION
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.